Joint Formulary & PAD

Co-careldopa - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
  • Tablets (slow release)
Associated Icons :
Restrictions / Comments :
Important
Can be prescribed upon recommendation from a specialist
 

Status 2

Red
Formulations :
  • Intestinal gel
Associated Icons :
BNF SPC
NHSE
Restrictions / Comments :

Documentation

PAD Profile

ChemicalSubstance :
Co-careldopa
Indication :
Parkinson's disease
Group Name :
Keywords :
levodopa, dopamine, PD
Brand Names Include :
Sinemet, Half Sinemet CR, Sinemet CR, Duodopa
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Co-careldopa is used to treat.

Committee Recommendations (2)

  • Levodopa is recommended as a first-line treatment in the early stages of Parkinson's disease where motor symptoms are impacting on quality of life.
  • Levodopa may also be a treatment choice in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
  • Levodopa may be considered in the treatment of nocturnal akinesia in Parkinson's disease.

Initiation may be carried out in Primary Care but only after recommendation by a specialist.

Patients in whom Parkinson's is suspected should be referred quickly and untreated to a specialist.

Levodopa-carbidopa (Duodopa®) intestinal gel is not for primary care prescribing.
Its specialist use is commissioned through NHS England.